Back

Teva prices $4.9 billion debt refinancing as NYSE direct listing begins

Verifying
  • Teva priced senior notes and began direct ordinary-share trading on the NYSE.
  • $4.9 billion equivalent was priced across five tranches maturing from 2032 through 2037.
  • Teva’s ordinary shares continue trading under TEVA on the NYSE and Tel Aviv Stock Exchange.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.